Idera Pharmaceuticals Inc
F:HXXB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth €-3.58 (228% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -10.4 | €2.8 |
0%
|
| Industry Average | 13.3 | €-3.58 |
-228%
|
| Country Average | 14.4 | €-3.86 |
-238%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
Idera Pharmaceuticals Inc
F:HXXB
|
174.4m EUR | -10.4 | -8.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 14.1 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 12.2 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 21 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13.4 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 41.5 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 10.4 | 30.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Idera Pharmaceuticals Inc
Glance View
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm designed and is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101.
